Boston Scientific Corp (BSX)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	1,984,000	1,929,000	1,565,000	1,484,000	1,194,000	866,000	1,104,000	908,000	1,078,000	991,000	281,000	-48,000	-350,000	-4,609,000	-4,291,000	-3,966,000	-3,532,000	513,000	878,000	1,079,000
Revenue (ttm)	US$ in thousands	13,974,000	10,508,000	10,348,000	9,999,000	9,228,000	12,104,000	11,689,000	11,502,000	11,625,000	11,168,000	10,855,000	9,774,000	9,553,000	9,751,000	9,790,000	10,420,000	10,349,000	10,035,000	9,758,000	9,649,000
Pretax margin		14.20%	18.36%	15.12%	14.84%	12.94%	7.15%	9.44%	7.89%	9.27%	8.87%	2.59%	-0.49%	-3.66%	-47.27%	-43.83%	-38.06%	-34.13%	5.11%	9.00%	11.18%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $1,984,000K ÷ $13,974,000K
= 14.20%

Boston Scientific Corp.'s pretax margin has shown a positive trend over the past eight quarters, indicating improving profitability before taxes. In Q4 2023, the company achieved the highest pretax margin of 13.95%, reflecting efficient cost management and revenue generation. This represents a significant increase from Q1 2022, where the pretax margin was at 7.45%.

The consistent upward trajectory in pretax margin suggests that Boston Scientific Corp. has been successful in controlling operating expenses and maximizing profits before accounting for taxes. This improvement could be attributed to factors such as revenue growth, cost-cutting measures, operational efficiencies, or a combination of these elements.

Overall, the trend in the pretax margin indicates that Boston Scientific Corp. has been effectively managing its financial performance and is on a positive trajectory in terms of profitability.